Volker Fendrich1, Detlef K Bartsch. 1. Department of Surgery, Philipps University Marburg, Baldingerstrasse, Marburg, Germany. fendrich@med.uni-marburg.de
Abstract
INTRODUCTION: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are uncommon but clinically challenging and fascinating tumors. GEP-NETs present as either functional or as nonfunctional tumors. Functional tumors are commonly associated with a specific hormonal syndrome directly related to a hormone secreted by the tumor, like gastrinomas with a Zollinger-Ellison syndrome or carcinoid syndrome in patients with neuroendocrine tumors (NET) of the ileum. Nonfunctional tumors do not secrete a hormone resulting in a clinical syndrome. METHODS: The natural course of GEP-NETs is highly variable. Small, benign neoplasms such as 90% of all insulinomas or gastric endocrine tumors type 1 are readily curable by surgical resection; however, most other GEP-NETs have a much less favorable prognosis. Patients with completely resected tumors generally have a good prognosis, and an aggressive surgical approach in patients with advanced disease may also prolong survival. CONCLUSIONS: This review focuses on the current standards of surgical treatment of gastric endocrine tumors, NETs of the pancreas (PNET) and NETs of the ileum. Although the evidence level is low in many instances due to the lack of randomized controlled trials, important treatment recommendations can be given.
INTRODUCTION:Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are uncommon but clinically challenging and fascinating tumors. GEP-NETs present as either functional or as nonfunctional tumors. Functional tumors are commonly associated with a specific hormonal syndrome directly related to a hormone secreted by the tumor, like gastrinomas with a Zollinger-Ellison syndrome or carcinoid syndrome in patients with neuroendocrine tumors (NET) of the ileum. Nonfunctional tumors do not secrete a hormone resulting in a clinical syndrome. METHODS: The natural course of GEP-NETs is highly variable. Small, benign neoplasms such as 90% of all insulinomas or gastric endocrine tumors type 1 are readily curable by surgical resection; however, most other GEP-NETs have a much less favorable prognosis. Patients with completely resected tumors generally have a good prognosis, and an aggressive surgical approach in patients with advanced disease may also prolong survival. CONCLUSIONS: This review focuses on the current standards of surgical treatment of gastric endocrine tumors, NETs of the pancreas (PNET) and NETs of the ileum. Although the evidence level is low in many instances due to the lack of randomized controlled trials, important treatment recommendations can be given.
Authors: U Plöckinger; G Rindi; R Arnold; B Eriksson; E P Krenning; W W de Herder; A Goede; M Caplin; K Oberg; J C Reubi; O Nilsson; G Delle Fave; P Ruszniewski; H Ahlman; B Wiedenmann Journal: Neuroendocrinology Date: 2005-04-18 Impact factor: 4.914
Authors: Francesco Tonelli; Geri Fratini; Gabriella Nesi; Maria Silvia Tommasi; Giacomo Batignani; Alberto Falchetti; Maria Luisa Brandi Journal: Ann Surg Date: 2006-07 Impact factor: 12.969
Authors: Jens Rosenau; Matthias J Bahr; Reinhard von Wasielewski; Michael Mengel; Hartmut H J Schmidt; Björn Nashan; Hauke Lang; Jürgen Klempnauer; Michael P Manns; Klaus H W Boeker Journal: Transplantation Date: 2002-02-15 Impact factor: 4.939
Authors: Jens Waldmann; Volker Fendrich; Nils Habbe; Detlef K Bartsch; Emily P Slater; Peter H Kann; Matthias Rothmund; Peter Langer Journal: World J Surg Date: 2009-06 Impact factor: 3.352
Authors: D Campana; F Nori; R Pezzilli; L Piscitelli; D Santini; E Brocchi; R Corinaldesi; P Tomassetti Journal: Endocr Relat Cancer Date: 2008-03 Impact factor: 5.678
Authors: G Rindi; G Klöppel; H Alhman; M Caplin; A Couvelard; W W de Herder; B Erikssson; A Falchetti; M Falconi; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann Journal: Virchows Arch Date: 2006-09-12 Impact factor: 4.064
Authors: Roeland F de Wilde; Barish H Edil; Ralph H Hruban; Anirban Maitra Journal: Nat Rev Gastroenterol Hepatol Date: 2012-02-07 Impact factor: 46.802
Authors: Jeffrey A Norton; Teresa Kim; Joseph Kim; Martin D McCarter; Kaitlyn J Kelly; Joyce Wong; Jason K Sicklick Journal: J Gastrointest Surg Date: 2017-08-14 Impact factor: 3.452